Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective

Value Health. 2014 Nov;17(7):A344-5. doi: 10.1016/j.jval.2014.08.696. Epub 2014 Oct 26.
No abstract available